Jump to content

Three COVID-19 Vaccines Developed in Thailand Are in Human Trials


snoop1130

Recommended Posts

9dbd7dc28a7123a6f87765297d0fc0e5_small.jpg

 

BANGKOK (NNT) - The National Research Council of Thailand and National Vaccine Institute have revealed that more than 20 COVID-19 vaccines are being researched and developed in Thailand, while three candidates are undergoing human trials.

 

ChulaCov19, an mRNA vaccine developed by Chulalongkorn University, is in the first phase of human trials on 72 volunteers. Two doses of the vaccine were given at an interval of 21 days.

 

The second one is HXP-GPOVac, an inactivated virus vaccine, jointly developed by the Faculty of Tropical Medicine at Mahidol University and the Government Pharmaceutical Organization. It is in the second phase of human trials in 460 volunteers. Two doses of the vaccine were injected at an interval of 28 days.

 

The third vaccine is Covigen, a DNA vaccine developed by Bionet Asia and Technovalia, which has started its first phase of human trials in 150 volunteers. Two doses of the vaccine were injected at an interval of 28 days.

 

nnt.jpg

-- © Copyright NNT 2021-07-06
 

 

Link to comment
Share on other sites

Guest
This topic is now closed to further replies.
  • Recently Browsing   0 members

    • No registered users viewing this page.





×
×
  • Create New...